A buyer cannot qualify this product by checking an assay result or a GMP logo alone. You need to verify the fixed-dose combination’s regulatory route, the site’s licence and Schedule M controls, the tablet’s analytical performance, stability evidence, and the records supplied with every batch before placing an order.
Key takeaways
- Request FDC approval or permission before assessing the manufacturing site.
- Ask for the site licence, Schedule M records and current GMP evidence.
- Require separate assay, impurity and dissolution data for both active ingredients.
- Set release tests, change controls and responsibilities in the quality agreement.
Confirm the Product’s Regulatory Identity Before Reviewing the Factory
Before reviewing a factory, confirm that the proposed gabapentin and nortriptyline tablet is an authorised product concept, not simply two marketed APIs combined. In India, classify it as a fixed-dose combination and request the FDC approval or permission under the Drugs and Cosmetics Act and New Drugs and Clinical Trials Rules.
A site manufacturing licence does not replace the central new-drug/FDC pathway when the combination is classified as a new drug.
Obtain records for the exact product:
- Approved strengths and gabapentin-to-nortriptyline dose ratio, including the rationale for combining them.
- Dosage form and release type: immediate-release or modified-release.
- Approved pack size, tablet description, composition, and proposed market label.
- Manufacturing-licence number and scope, checked against the approved product and premises.
- Applicable Indian Pharmacopoeia monograph for each active ingredient, plus product-specific limits for assay, impurities, dosage-unit uniformity, dissolution, and stability.
- Bioequivalence evidence for the combination and each active ingredient, or a documented biowaiver justification based on the applicable regulator’s criteria, strengths, excipients, permeability, solubility, and comparative dissolution.
Do not accept “both ingredients are already marketed” as evidence that the combination is cleared. Ask whether the manufacturer has assessed compatibility, segregation during blending, two-active content uniformity, and nitrosamine risk associated with nortriptyline, including API and excipient suppliers. Match every answer to the approval, formula, release type, and pack size you intend to buy.
Check the Site Licence, Schedule M System and GMP Evidence
Request the current manufacturing licence, not a brochure. The document must show the manufacturing licence number, licence scope, dosage form, approved strengths, and approved premises. Confirm that the address on the licence matches the site producing the tablets; a sister company or separate warehouse does not establish authorisation.
Use the documents below to test both authorisation and control:
| Document | What it demonstrates | What to verify |
|---|---|---|
| Manufacturing licence | Legal permission to manufacture | Licence number, tablet scope, strengths, premises and validity |
| Schedule M records | Compliance with India’s revised GMP requirements | Pharmaceutical quality system, qualified personnel, validation, production and laboratory controls, complaints, recalls and self-inspection |
| WHO-GMP certificate | An inspection-based GMP status | Issuer, covered premises, dosage forms and expiry; WHO-GMP does not prove complete current Schedule M compliance |
| Quality manual and procedures | How the pharmaceutical quality system operates | Deviations, change control, OOS and OOT investigations, batch release and data integrity |
| Quality agreement | Allocated contract-manufacturing duties | Recall, stability, supplier qualification, records, complaints and regulatory inspections |
Ask for the latest inspection report or corrective-action closure evidence, training records, validation summaries and recent internal-audit results. For export supply, map the system to the destination regulator rather than treating an Indian licence as sufficient.
Do not confuse these standards: ICH Q7 addresses API manufacture, ICH Q9 addresses quality-risk management, and ICH Q10 describes the pharmaceutical quality system. They support different controls and are not interchangeable certifications.
Demand Product-Specific Testing for Both Active Ingredients
A batch-average assay cannot show that every tablet contains the intended gabapentin–nortriptyline doses. Demand specifications and validated methods that test both active ingredients in the finished product and control the manufacturing process that creates each unit.
| Control | Evidence to demand | Failure it catches |
|---|---|---|
| Identification and assay | Separate identification and assay for gabapentin and nortriptyline | Wrong ingredient, incorrect dose, or API substitution |
| Uniformity and release | Uniformity of dosage units, dissolution, and disintegration results for the actual formulation | Tablet-to-tablet dose variation or incomplete release |
| Physical performance | Friability, hardness, compression force records, and metal detection checks | Chipping, unsuitable mechanical strength, or metal contamination |
| Impurities and microbiology | Related substances, degradation products, and microbial limits where applicable | Chemical breakdown or unacceptable microbial quality |
For uniformity of dosage units, request results from 10 individual tablets, not a pooled sample. Under USP <905>, the initial acceptance value must be 15.0 or less; if it fails, the prescribed additional-unit stage and criteria apply. A passing average assay can conceal clinically important variation.
The laboratory method must be a stability-indicating method that separates each active from relevant degradation products. Ask for method validation, system-suitability results, and dissolution data after stability storage, not a single nominal percentage.
Review blend uniformity results for both actives and controls against segregation during transfer and compression. Require documented sampling locations, validated mixing time, compression-force limits, and investigation of every OOS result before retesting or averaging.
Compare Immediate-Release and Modified-Release Evidence
Choose an immediate-release tablet when the clinical regimen does not require prolonged exposure, delayed release, or reduced dosing frequency. Choose a sustained-release formulation only when pharmacokinetic, clinical, and manufacturing evidence shows that modified-release provides a benefit without dose-dumping or difficult dose adjustment.
| Design | Evidence to require | Decision signal |
|---|---|---|
| Immediate-release tablet | Validated, stability-indicating dissolution method; disintegration; assay and uniformity for both actives; consistent dissolution profile across batches | Rapid, repeatable release matches the intended dosing and clinical data |
| Sustained-release formulation | Mechanism-specific dissolution profile at multiple time points, discriminatory method, release-controlling excipient data, dose-dumping assessment, and comparative pharmacokinetic evidence | Controlled release remains consistent after storage and matches the proposed regimen |
Do not accept a single nominal dissolution percentage as proof. Request method validation, tablet-to-tablet results, profile consistency, and data after stability storage; test the formulation in the actual dosage form and apparatus.
The stability protocol must match the market and pack. For hot, humid regions, long-term stability commonly includes Zone IVb 30°C/75% RH, alongside accelerated stability, with results supporting the proposed shelf life. A blister’s moisture protection cannot be transferred automatically to a bottle; evaluate each configuration, including seal integrity and in-use exposure.
Because nortriptyline has a secondary amine, require a documented nitrosamine risk evaluation covering APIs, excipients, water, recovered solvents, processing aids, and changes. Also require HBEL and PDE controls where shared equipment creates cross-contamination risk. Revisit both assessments after supplier, process, or packaging changes.
Use a Technical and Quality-Agreement Checklist Before Ordering
Before paying a deposit, obtain the technical file and make each responsibility enforceable in a signed quality agreement. A purchase order covering price, minimum order quantity and delivery time does not assign GMP accountability.
- Request the product development report, master manufacturing formula, batch manufacturing record, finished-product specification, validation summary and stability protocol. The file must identify the formulation, release type, tests, acceptance limits and retained-sample period.
- Request the API certificate of analysis for gabapentin and nortriptyline, the excipient specifications, supplier-qualification evidence and a nitrosamine risk evaluation covering the secondary amine, solvents, water, processing aids and later supplier changes.
- Require written procedures for data integrity, OOS/OOT investigations, deviations, change control, complaints, recall, pharmacovigilance and batch release. Define who approves each record and who contacts the regulator.
| Control | Manufacturer must provide | Buyer must verify |
|---|---|---|
| Batch release | Authorised release record and complete BMR | Named release authority and document access |
| Quality events | OOS/OOT, deviation and change-control investigations | No retest-only closure; documented root cause and CAPA |
| Distribution | GDP transport, receipt, storage and traceability records | Temperature logs, damaged-blister handling and FEFO |
| Post-market | Complaint, recall and pharmacovigilance procedure | Contact times, mock-recall participation and reporting route |
Ask Chemsroot Pharmaceutical to identify the exact manufacturing site, licence scope and responsible quality contacts for the selected product rather than relying on catalogue wording. Record destination-country requirements, audit rights, data retention, stability commitments and notification periods for any change before ordering.
Frequently asked questions
What should you confirm before reviewing a gabapentin and nortriptyline tablet factory?
Confirm that the product is authorised as a fixed-dose combination and request the FDC approval or permission under India’s Drugs and Cosmetics Act and New Drugs and Clinical Trials Rules.
Which manufacturing documents should you request from the site?
Request a copy of the site licence, Schedule M compliance records, current GMP evidence, and documents showing that the facility is authorised to manufacture the proposed tablet.
What testing evidence should a gabapentin and nortriptyline tablet manufacturer provide?
Request product-specific results for identification, assay, related substances, content uniformity, dissolution, microbial quality where applicable, and stability for both active ingredients.
What should a technical and quality agreement cover before ordering?
Define specifications, batch-release testing, approved suppliers, change control, deviation handling, complaints, recalls, data access, responsibilities and required notification timelines.
